Trastuzumab emtansine
- CAS No.
- 1018448-65-1
- Chemical Name:
- Trastuzumab emtansine
- Synonyms
- T-DM1;Kadcyla;PRO132365;trastuzumab-DM1;trastuzumab-MCC-DM1;trastuzumab emtansine;Ado-trastuzumab emtansine;Ado-trastuzuMab-eMtansine cas nr;Ado-trastuzumab Emtansine (TDM-1);trastuzumab-MCC-DM1 antibody-drug conjugate
- CBNumber:
- CB12672561
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MFCD28138412
- MOL File:
- Mol file
- MSDS File:
- SDS
| storage temp. | Store at -20°C |
|---|---|
| NCI Dictionary of Cancer Terms | ado-trastuzumab emtansine |
| FDA UNII | SE2KH7T06F |
| NCI Drug Dictionary | ado trastuzumab emtansine |
| ATC code | L01XC14 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |    GHS08,GHS07,GHS06 |
|---|---|
| Signal word | Danger |
| Hazard statements | H300-H371-H315-H360-H351-H340-H330 |
| Precautionary statements | P264-P270-P301+P310-P321-P330-P405-P501-P260-P264-P270-P309+P311-P405-P501-P264-P280-P302+P352-P321-P332+P313-P362-P201-P202-P281-P308+P313-P405-P501-P260-P271-P284-P304+P340-P310-P320-P403+P233-P405-P501 |
Trastuzumab emtansine Chemical Properties,Uses,Production
Description
T-DM1 is a human epidermal growth factor receptor (HER2)-targeted antibody drug conjugate (ADC) that was approved in February 2013 by the US FDA for use as a single agent for the treatment of patients with HER2-positive, metastatic breast cancer (mBC) who previously received treatment with trastuzumab and a taxane, separately, or in combination. T-DM1 is composed of trastuzumab linked to the potent cytotoxic microtubule polymerization inhibitor DM1 (derivative of maytansine) via a stable uncleavable thioether linker. T-DM1 is produced by chemically crosslinking the cytotoxic maytansinoid derivative to the lysine residues of trastuzumab such that there is an average of 3.5 cytotoxic molecules linked to each antibody. In addition to delivering DM1 to tumor cells, T-DM1 retains the effector functions of trastuzumab, including inhibition of HER2-mediated signal transduction and activation of antibodydependent cell-mediated cytotoxicity.
Originator
Genentech, a member of the Roche Group (United States)
brand name
Kadcyla
Synthesis
First, commercial 3-mercaptopropionic acid (191) was treated
with methanethiolsufonate to give the corresponding methyldithio
analog 192 in 90% yield. Activation of the acid with N-hydroxysuccinimide
in the presence of 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDCI) provided the activated ester 193, which was
reacted with N-methyl-L-alanine (194) to give acid 195 in 60% yield
from compound 192.
Preparation of the DM1 linker-payload is described in
above. The starting material used for the production of DM1
is ansamitocin P-3 (196), which is produced via fermentation
of the microorganism Actinosynnema pretiosum. The ester group
of 196 was removed using a reductive process in the presence of
lithium trimethoxyaluminum hydride to give maytansinol 197 in
85% yield. The use of reductive conditions was required to
avoid subsequent elimination to the a,b-unsaturated amide.
Esterification with 195 in the presence of 1,3-dicyclohexylcarbodiimide
(DCC) and zinc chloride provided DM1¨CSMe 198 in 32%
yield. Reductive removal of the dithiane using dithiothreitol
(DTT) in aqueous buffer at pH 7.5 gave DM1 thiol 199 in 76% yield,
which was utilized in the conjugation to trastuzumab (200).
Completion of the synthesis of trastuzumab emtansine is
described in above. The surface accessible lysine residues of trastuzumab (200) were treated with succinimidyl-4-(N-maleimidomethyl)-
cyclohexane-carboxylate (SMCC, 201) in pH 7.0 buffer
to give amide 202 with approximately four SMCC molecules added
per antibody in 88% yield. Next, the free thiol group of
DM1 (199) was conjugated to the maleimide groups present on
202 to give trastuzumab emtansine (XXV) with an average 3.5
drug molecules loaded per antibody.
Trastuzumab emtansine Preparation Products And Raw materials
Raw materials
Preparation Products
Trastuzumab emtansine Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | info@tianfuchem.com | China | 21691 | 55 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19553 | 58 |
| Career Henan Chemica Co | +86-0371-86658258 15093356674; | laboratory@coreychem.com | China | 30255 | 58 |
| Wuhan Topule Biopharmaceutical Co., Ltd | +8618327326525 | masar@topule.com | China | 8474 | 58 |
| LEAPCHEM CO., LTD. | +86-852-30606658 | market18@leapchem.com | China | 43348 | 58 |
| Shanghai jerryxing Biomedical Technology Co., Ltd | 17721492509 | 643638326@qq.com | China | 5347 | 58 |
| Chembest Research Laboratories Limited | 021-20908456 | sales@BioChemBest.com | China | 6011 | 61 |
| Wuhan Sunrise Technology Development Co., Ltd. | 027-027-83314682 13554138826 | whsrtech@vip.163.com | China | 300 | 62 |
| EnliPharma Technology Co., Ltd | 0551-66399836 18955197623 | sales@enlipharma.com | China | 1874 | 55 |
| Nanjing Vital Chemical Co., Ltd. | 025-87193546 18652950785 | chemweiao@163.com | China | 9030 | 60 |